South Korea · Delayed Price · Currency is KRW Finemedix Statistics
Total Valuation
Finemedix has a market cap or net worth of KRW 34.21 billion. The enterprise value is 30.76 billion.
| Market Cap | 34.21B |
| Enterprise Value | 30.76B |
Important Dates
The last earnings date was Friday, August 28, 2026.
| Earnings Date | Aug 28, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Finemedix has 5.43 million shares outstanding. The number of shares has increased by 2.73% in one year.
| Current Share Class | 5.43M |
| Shares Outstanding | 5.43M |
| Shares Change (YoY) | +2.73% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 43.14% |
| Owned by Institutions (%) | 1.16% |
| Float | 3.09M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 2.99 |
| PB Ratio | 1.79 |
| P/TBV Ratio | 1.80 |
| P/FCF Ratio | 49.32 |
| P/OCF Ratio | 37.20 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 2.69 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | 44.34 |
Financial Position
The company has a current ratio of 10.83, with a Debt / Equity ratio of 0.12.
| Current Ratio | 10.83 |
| Quick Ratio | 7.15 |
| Debt / Equity | 0.12 |
| Debt / EBITDA | n/a |
| Debt / FCF | 3.21 |
| Interest Coverage | -9.81 |
Financial Efficiency
Return on equity (ROE) is -3.12% and return on invested capital (ROIC) is -7.50%.
| Return on Equity (ROE) | -3.12% |
| Return on Assets (ROA) | -3.02% |
| Return on Invested Capital (ROIC) | -7.50% |
| Return on Capital Employed (ROCE) | -5.09% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.47 |
| Inventory Turnover | 1.16 |
Taxes
| Income Tax | -542.64M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -26.32% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -26.32% |
| 50-Day Moving Average | 5,660.10 |
| 200-Day Moving Average | 6,502.30 |
| Relative Strength Index (RSI) | 58.34 |
| Average Volume (20 Days) | 5,498 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Finemedix had revenue of KRW 11.43 billion and -599.38 million in losses. Loss per share was -110.38.
| Revenue | 11.43B |
| Gross Profit | 5.93B |
| Operating Income | -1.17B |
| Pretax Income | -1.14B |
| Net Income | -599.38M |
| EBITDA | -234.18M |
| EBIT | -1.17B |
| Loss Per Share | -110.38 |
Balance Sheet
The company has 5.68 billion in cash and 2.23 billion in debt, with a net cash position of 3.46 billion or 636.24 per share.
| Cash & Cash Equivalents | 5.68B |
| Total Debt | 2.23B |
| Net Cash | 3.46B |
| Net Cash Per Share | 636.24 |
| Equity (Book Value) | 19.13B |
| Book Value Per Share | 3,522.65 |
| Working Capital | 12.20B |
Cash Flow
In the last 12 months, operating cash flow was 919.75 million and capital expenditures -226.04 million, giving a free cash flow of 693.71 million.
| Operating Cash Flow | 919.75M |
| Capital Expenditures | -226.04M |
| Depreciation & Amortization | 932.11M |
| Net Borrowing | -308.91M |
| Free Cash Flow | 693.71M |
| FCF Per Share | 127.75 |
Margins
Gross margin is 51.93%, with operating and profit margins of -10.21% and -5.25%.
| Gross Margin | 51.93% |
| Operating Margin | -10.21% |
| Pretax Margin | -9.99% |
| Profit Margin | -5.25% |
| EBITDA Margin | -2.05% |
| EBIT Margin | -10.21% |
| FCF Margin | 6.07% |
Dividends & Yields
Finemedix does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -2.73% |
| Shareholder Yield | -2.73% |
| Earnings Yield | -1.75% |
| FCF Yield | 2.03% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Finemedix has an Altman Z-Score of 5.8 and a Piotroski F-Score of 3.
| Altman Z-Score | 5.8 |
| Piotroski F-Score | 3 |